BCRX · Biocryst Pharmaceuticals Inc
$9.74
-0.07 (-0.71%)
At close · Aug 14
Market Cap
$2.49B
Shares
255.54M
Biocryst Pharmaceuticals Inc Earnings Call Transcripts
Every quarterly earnings call for Biocryst Pharmaceuticals Inc (BCRX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲85%
$75.83M
−$42.52M
'22 Q3
22-11-01
▲68.7%
$79.55M
−$71.54M
'22 Q4
23-01-09
▲37.8%
$68.78M
−$53.33M
'23 Q1
23-05-03
▲25.9%
$82.49M
−$75.33M
'23 Q2
23-08-03
▲14.4%
$86.74M
−$36.15M
'23 Q3
23-11-02
▲17.4%
$93.40M
−$61.73M
'23 Q4
24-02-26
▲34.9%
$92.76M
−$35.38M
'24 Q1
24-05-06
▲32.5%
$109.33M
−$12.67M
'24 Q2
24-08-05
▲35%
$117.08M
−$14.03M
'24 Q3
24-11-04
▲40.8%
$131.53M
−$26.80M
'24 Q4
25-02-24
▲56.9%
$145.53M
$32,000
'25 Q1
25-05-05
▲49.4%
$163.35M
$5.08M
'25 Q2
25-08-04
▲36.1%
$159.40M
$12.90M
'25 Q3
25-10-14
▲209.1%
$406.56M
$245.84M
'25 Q4
26-02-26
▲7.5%
$156.41M
−$721.81M
'26 Q1
26-05-06
LATEST
▲33.6%
$218.25M
$78.39M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
BioCryst Second Quarter 2026 Earnings Call
Confident tone
Pediatric launch (Orladeyo pellets)
Demand momentum and new prescribers
Patient retention / stickiness
Revenue
$218.25M
▲ 33.6% YoY Diluted EPS
$0.30
▲ 1400% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Biocryst Pharmaceuticals Inc Q1 FY2026 Earnings Call
Confident tone
ORLADEYO commercial performance
Navenibart / ALPHA-ORBIT Phase 3
Pediatric pellet launch and manufacturing delay
Revenue
$156.41M
▲ 7.5% YoY Diluted EPS
$-2.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Biocryst Pharmaceuticals Inc Q4 FY2025 Earnings Call
Confident tone
HAE market structure and competition
ORLADEYO commercial performance and growth
Navenibart Phase III program
Revenue
$406.56M*
▲ 209.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-14
Biocryst Pharmaceuticals Inc Q3 FY2025 Earnings Call
Confident tone
ORLADEYO revenue growth and guidance raise
BCX17725 for Netherton syndrome
Astria acquisition and navenibart asset
Revenue
$159.40M
▲ 36.1% YoY Diluted EPS
$0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Biocryst Pharmaceuticals Inc Q2 FY2025 Earnings Call
Confident tone
ORLADEYO commercial momentum
CEO succession and BioCryst 2.0 / BD strategy
Pipeline programs (Netherton, DME)
Revenue
$163.35M
▲ 49.4% YoY Diluted EPS
$0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Biocryst Pharmaceuticals Inc Q1 FY2025 Earnings Call
Confident tone
ORLADEYO commercial performance
Profitability and financial strength
Pipeline progress (BCX17725, avoralstat)
Revenue
$145.53M
▲ 56.9% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-24
Biocryst Pharmaceuticals Inc Q4 FY2024 Earnings Call
Confident tone
Pediatric Orladeo label expansion
BCX1775 for Netherton syndrome
Medicare / Inflation Reduction Act impact
Revenue
$131.53M*
▲ 40.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Biocryst Pharmaceuticals Inc Q3 FY2024 Earnings Call
Confident tone
BCX17725 for Netherton Syndrome Pipeline
Pediatric Label Expansion and ORLADEYO Granules
Medicare and Non-Commercial Access Risks
Revenue
$117.08M
▲ 35% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Biocryst Pharmaceuticals Inc Q2 FY2024 Earnings Call
Confident tone
ORLADEYO Commercial Performance
2024 Revenue Guidance Raise
Long-Term $1B Peak Sales Opportunity
Revenue
$109.33M
▲ 32.5% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Biocryst Pharmaceuticals Inc Q1 FY2024 Earnings Call
Confident tone
ORLADEYO commercial performance
Pipeline advancement
Pediatric program and filing
Revenue
$92.76M
▲ 34.9% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Biocryst Pharmaceuticals Inc Q4 FY2023 Earnings Call
Confident tone
ORLADEYO Commercial Performance
Real-World Evidence and Clinical Data
HAE Market Dynamics
Revenue
$93.40M*
▲ 17.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Biocryst Pharmaceuticals Inc Q3 FY2023 Earnings Call
Revenue
$86.74M
▲ 14.4% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Biocryst Pharmaceuticals Inc Q2 FY2023 Earnings Call
Revenue
$82.49M
▲ 25.9% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Biocryst Pharmaceuticals Inc Q1 FY2023 Earnings Call
Revenue
$68.78M
▲ 37.8% YoY Diluted EPS
$-0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Biocryst Pharmaceuticals Inc Q4 FY2022 Earnings Call
Revenue
$79.55M*
▲ 68.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Biocryst Pharmaceuticals Inc Q3 FY2022 Earnings Call
Revenue
$75.83M
▲ 85% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Biocryst Pharmaceuticals Inc Q2 FY2022 Earnings Call
Revenue
$65.53M
▲ 31.2% YoY Diluted EPS
$-0.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Biocryst Pharmaceuticals Inc Q1 FY2022 Earnings Call
Revenue
$49.92M
▲ 161.9% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Biocryst Pharmaceuticals Inc Q4 FY2021 Earnings Call
Revenue
$47.16M*
▲ 1074.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Biocryst Pharmaceuticals Inc Q3 FY2021 Earnings Call
Revenue
$40.99M
▲ 571.8% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Biocryst Pharmaceuticals Inc Q2 FY2021 Earnings Call
Revenue
$49.96M
▲ 1640.1% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Biocryst Pharmaceuticals Inc Q1 FY2021 Earnings Call
Revenue
$19.06M
▲ 295.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Biocryst Pharmaceuticals Inc Q4 FY2020 Earnings Call
Revenue
$4.02M
▼ 89.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Biocryst Pharmaceuticals Inc Q3 FY2020 Earnings Call
Revenue
$6.10M
▲ 243.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Biocryst Pharmaceuticals Inc Q2 FY2020 Earnings Call
Revenue
$2.87M
▲ 98.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Biocryst Pharmaceuticals Inc Q1 FY2020 Earnings Call
Revenue
$4.82M
▼ 18.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Biocryst Pharmaceuticals Inc Q4 FY2019 Earnings Call
Revenue
$39.73M
▲ 1355.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
882796
CUSIP
09058V103
13F (30d)
309 filings
302 filers
Visit website
Investor relations